Welcome and Introduction to Vi3C

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Amit Sanyal, MD: A Clinician’s Perspective

Oct

Today In Oncology

Welcome and Introduction to Vi3C

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Amit Sanyal, MD: A Clinician’s Perspective

Long-Term Disease Control From SBRT Equal to Surgery in Localized Prostate Cancer

Prostate Cancer Higher Saturated Fat Intake May Be Linked to Worse Outcomes

The Wistar Institute Names New President and Chief Executive Officer

Early Research Links Abdominal Obesity to Increased Lung Cancer Risk

HER2-Negative Advanced Gastric Cancers First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit